Patrick Donovan
Scottsdale, AZNPI 1679579619
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 161 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$460
- Novartis$323
- Pfizer$196
- Genentech USA, Inc.$180
- AstraZeneca$154
- E.r. Squibb & Sons, L.L.C.$143
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,034100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 3 | $460 |
| Novartis | 14 | $323 |
| Pfizer | 16 | $196 |
| Genentech USA, Inc. | 11 | $180 |
| AstraZeneca(2 entities) | 11 | $154 |
| E.r. Squibb & Sons, L.L.C. | 14 | $143 |
| Merck | 11 | $139 |
| Amgen | 7 | $136 |
| Puma Biotechnology, Inc. | 6 | $122 |
| Bayer | 7 | $118 |
| Johnson & Johnson(2 entities) | 7 | $117 |
| Exelixis Inc. | 5 | $88 |
| Astellas Pharma US Inc | 5 | $77 |
| Boehringer Ingelheim | 3 | $69 |
| Sanofi | 4 | $67 |
| Bristol Myers Squibb | 3 | $61 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $55 |
| EMD Serono, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Incyte Corporation | 3 | $45 |
| Rigel Pharmaceuticals, Inc. | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Lilly USA, LLC | 2 | $28 |
| Gilead(2 entities) | 2 | $27 |
| Array Biopharma Inc | 2 | $26 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $25 |
| Spectrum Pharmaceuticals Inc. | 1 | $22 |
| Shionogi Inc | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Aurobindo Pharma USA, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.